Nothing Special   »   [go: up one dir, main page]

EA202090563A1 - Анти-pacap антитело - Google Patents

Анти-pacap антитело

Info

Publication number
EA202090563A1
EA202090563A1 EA202090563A EA202090563A EA202090563A1 EA 202090563 A1 EA202090563 A1 EA 202090563A1 EA 202090563 A EA202090563 A EA 202090563A EA 202090563 A EA202090563 A EA 202090563A EA 202090563 A1 EA202090563 A1 EA 202090563A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
pacap antibody
migraine
methods
compositions containing
Prior art date
Application number
EA202090563A
Other languages
English (en)
Inventor
Кейтрин Бротигем Бейдлер
Майкл Парвин Джонсон
Четанкумар Натварлал Пател
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA202090563A1 publication Critical patent/EA202090563A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Представлены антитела к активирующему аденилатциклазу гипофиза пептиду человека, композиции, содержащие такие антитела, и способы применения таких антител для лечения боли, включая головную боль и/или мигрень.
EA202090563A 2017-09-29 2018-09-20 Анти-pacap антитело EA202090563A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565278P 2017-09-29 2017-09-29
PCT/US2018/051898 WO2019067293A1 (en) 2017-09-29 2018-09-20 ANTI-PACAP ANTIBODIES

Publications (1)

Publication Number Publication Date
EA202090563A1 true EA202090563A1 (ru) 2020-06-24

Family

ID=63794713

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090563A EA202090563A1 (ru) 2017-09-29 2018-09-20 Анти-pacap антитело

Country Status (25)

Country Link
US (3) US10519225B2 (ru)
EP (1) EP3688035A1 (ru)
JP (2) JP6952888B2 (ru)
KR (1) KR102453573B1 (ru)
CN (1) CN111164105B (ru)
AR (1) AR113022A1 (ru)
AU (1) AU2018341959B2 (ru)
BR (1) BR112020003628A2 (ru)
CA (1) CA3077304C (ru)
CL (1) CL2020000705A1 (ru)
CO (1) CO2020002170A2 (ru)
CR (1) CR20200127A (ru)
DO (1) DOP2020000060A (ru)
EA (1) EA202090563A1 (ru)
EC (1) ECSP20020293A (ru)
IL (1) IL273529A (ru)
JO (1) JOP20200069A1 (ru)
MA (1) MA50654A (ru)
MX (1) MX2020003563A (ru)
NZ (1) NZ762312A (ru)
PE (1) PE20201494A1 (ru)
SG (1) SG11202002572YA (ru)
TW (1) TWI701260B (ru)
WO (1) WO2019067293A1 (ru)
ZA (1) ZA202001058B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
AU2017250815B2 (en) 2016-04-15 2023-11-23 H. Lundbeck A/S. Humanized anti-PACAP antibodies and uses thereof
KR20220054689A (ko) 2019-10-15 2022-05-03 일라이 릴리 앤드 캄파니 재조합적으로 조작된, 리파제/에스테라제-결핍 포유동물 세포주
TW202330607A (zh) * 2021-09-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｃｇｒｐ和ｐａｃａｐ的抗原結合分子及其醫藥用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991014786A1 (en) 1990-03-17 1991-10-03 Takeda Chemical Industries, Ltd. Antibody to pituitary adenylate cyclase activating peptide-pacap, hybridoma and assay for pacap
US6037321A (en) 1995-05-03 2000-03-14 Biostar Inc. Fusion proteins comprising vasoactive intestinal peptide or PACAP
FR2826747B1 (fr) 2001-07-02 2005-02-25 Gemplus Card Int Procede et dispositif de traitement de donnees pour la personnalisation d'une application sur un dispositif communicant portatif, par exemple une carte a puce
WO2004062684A2 (en) 2003-01-16 2004-07-29 D. Collen Research Foundation Vzw Onderwijs En Navorsing Campus Gasthuisberg K.U. Leuven Treatment of thrombocytopenia with inhibitors of pacap
WO2012106407A2 (en) * 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
JP6064861B2 (ja) 2013-03-05 2017-01-25 株式会社デンソー 熱電変換装置の製造方法
WO2014144632A2 (en) * 2013-03-15 2014-09-18 Amgen Inc. Human pac1 antibodies
EP3035950A4 (en) 2013-08-14 2017-05-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
JP6752222B2 (ja) 2015-04-16 2020-09-09 アルダー・バイオファーマシューティカルズ・インコーポレーテッド 羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
MA43567A (fr) * 2015-12-15 2018-11-14 Amgen Inc Anticorps pacap et leurs utilisations
WO2017142961A1 (en) 2016-02-16 2017-08-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Treatment of traumatic brain injury or stroke

Also Published As

Publication number Publication date
MX2020003563A (es) 2020-08-03
AU2018341959B2 (en) 2021-11-25
JP6952888B2 (ja) 2021-10-27
JP2020535167A (ja) 2020-12-03
US20210171616A1 (en) 2021-06-10
CA3077304C (en) 2023-08-01
US20200131256A1 (en) 2020-04-30
JOP20200069A1 (ar) 2020-04-28
CA3077304A1 (en) 2019-04-04
KR102453573B1 (ko) 2022-10-12
ZA202001058B (en) 2022-06-29
PE20201494A1 (es) 2020-12-29
CL2020000705A1 (es) 2020-09-11
KR20200040881A (ko) 2020-04-20
NZ762312A (en) 2022-11-25
BR112020003628A2 (pt) 2020-09-01
MA50654A (fr) 2020-08-05
WO2019067293A1 (en) 2019-04-04
JP2022000049A (ja) 2022-01-04
CN111164105A (zh) 2020-05-15
SG11202002572YA (en) 2020-04-29
TW201920280A (zh) 2019-06-01
AR113022A1 (es) 2020-01-15
CR20200127A (es) 2020-04-08
US10519225B2 (en) 2019-12-31
AU2018341959A1 (en) 2020-03-05
EP3688035A1 (en) 2020-08-05
US20190100579A1 (en) 2019-04-04
DOP2020000060A (es) 2020-08-15
CO2020002170A2 (es) 2020-04-01
IL273529A (en) 2020-05-31
JP7221352B2 (ja) 2023-02-13
TWI701260B (zh) 2020-08-11
US10954292B2 (en) 2021-03-23
ECSP20020293A (es) 2020-06-30
CN111164105B (zh) 2023-07-04

Similar Documents

Publication Publication Date Title
PH12018501882A1 (en) Binding proteins and methods of use thereof
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
EA202190609A1 (ru) Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
PH12019501405A1 (en) Anti-neuropilin antigen-binding proteins and methods of use thereof
EA202090563A1 (ru) Анти-pacap антитело
EA202191785A1 (ru) Антитела к ctla4 и способы их применения
EA201592203A1 (ru) Способы лечения таупатии
AR095611A1 (es) Anticuerpos que se unen al receptor del polipéptido activador de la adenilato ciclasa pituitaria humana tipo i (hpac1)
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA201992883A1 (ru) АНТИТЕЛА К TrkB
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
MX2020006976A (es) Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos.
EA201992747A1 (ru) Антитела к fam19a5 и их применение
EA202091666A1 (ru) Способ получения препаратов оил, обогащенных специфическими для опухолевых антигенов t-клетками
EA202092279A1 (ru) Антитела к mica и/или micb и их применение
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения
EA201990927A1 (ru) Антитела против lag-3 и способы их применения